Allarity Therapeutics secures first lab services contract with European biotech company
ALLR•Allarity Therapeutics secured its first revenue-generating contract under its CLIA-certified laboratory services strategy. The agreement covers development and validation of a precision oncology predictive device intended for US use; successful completion could lead to recurring testing and service revenue.
1. Contract details
The contract with a European biotechnology company covers development and validation services for a precision oncology predictive device intended for use in the US. Successful completion could lead to recurring commercial testing and CLIA-related service revenue. Allarity said stenoparib remains its top development priority.
